Episode 83
Biotech Hangout
00:00
Gene Therapy Pricing and Decision-Making Process
This chapter explores the decision-making process and pricing strategy behind Bluebird's gene therapy approval for sickle cell disease. It highlights the mistakes made by Bluebird, the presence of a black box warning, and the interesting contrast between two companies' pricing decisions.
Play episode from 30:47
Transcript
